Hepatic‐Accumulated Obeticholic Acid and Atorvastatin Self‐Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic‐Associated Fatty Liver Disease

Hepatic‐Accumulated Obeticholic Acid and Atorvastatin Self‐Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic‐Associated Fatty Liver Disease

Abstract Exploration of medicines for efficient and safe management of metabolic‐associated fatty liver disease (MAFLD) remains a challenge. Obeticholic acid (OCA), a selective farnesoid X receptor agonist, has been reported to ameliorate injury and inflammation in various liver diseases. However, i...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Huanfen Lu, Zhenglan Ban, Kai Xiao, Madi Sun, Yongbo Liu, Fangman Chen, Tongfei Shi, Li Chen, Dan Shao, Ming Zhang, Wei Li
Materialtyp: Artikel
Språk:English
Publicerad: Wiley 2024-03-01
Serie:Advanced Science
Ämnen:
atorvastatin
inflammation
metabolic‐associated fatty liver disease
nanocrystal
obeticholic acid
Länkar:https://doi.org/10.1002/advs.202308866

Internet

https://doi.org/10.1002/advs.202308866

Liknande verk